Vyant Bio, Inc.
https://www.vyantbio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vyant Bio, Inc.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Regenerative Medicine Comes Of Age – In The Age Of COVID-19
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Bio Type, Inc.
- Cancer Genetics, Inc.
- Gentris Corporation
- Pathwork Diagnostics
- Response Genetics, Inc.
- StemoniX Inc.
- vivoPharm Pty. Ltd.